a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10007164				
Filing Date		2001-11-30				
First Named Inventor	Richa	rd Gore				
Art Unit		2151				
Examiner Name	Kama	d Divecha				
Attorney Docket Number		2705-702				

			Remove					
		Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Releva		Lines where ges or Relevant	
	1	5761502		1998-06-02	Jacobs			
	2	6000045		1999-12-07	Lewis			
	3	6253339		2001-06-26	Tse et al.			
	4	6430712		2002-08-06	Lewis			
	5	6438707		2002-08-20	Ronstrom			
	6	6966015		2005-11-15	Steinberg et al.			
If you wis	h to a	dd additional U.S. Pater	rt citatio	n information pl	ease click the Add button.		Add	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Releva		Lines where ges or Relevant

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10007164			
Filing Date		2001-11-30			
First Named Inventor	Richard Gore				
Art Unit		2151			
Examiner Name	Kama	mal Divecha			
Attorney Docket Number		2705-702			

	1	20020191624		2002-12	2-19	Onweller et al.					
	2	20030115508		2003-06	3-19	Alietai.					
	3	20030149919		2003-08	3-07	Greenwald et al.					
	4	20040015619		2004-01-22		Brown et al.					
	5	20040153835		2004-08-05		Song et al.					
	6	20050216784		2005-09-29		Srinivasan et a	1.				
	7	20050216785		2005-09-29		Suzuki et al.					
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	n citatio	n information p	olease click the Add	d buttor	Add		
				FOREIG	GN PAT	TENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Countr Code ²			Publication Date	Name of Patentee Applicant of cited Document	e or		or Relevant	
	1										
If you wis	h to a	dd additional Foreign Pa	atent Do	cument	citation	information pl	lease click the Add	button			
	NON-PATENT LITERATURE DOCUMENTS Remove										

Attorney Docket Number

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1		

2705-702

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTIO Patent Documents at year LISPTIO, CODE or MEPE 901.6.2 Editor office that issued the document, by the holietier code (WIPO Standard ST.3). 3 For disparsee patent obcuments, by the indication of the year of the Propriet many percectible seed number of the Pederal concerns, if Norid of countents by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 3 Applicant is to place a check mark here if Expolite Improaces the relation to a standard.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10007164			
Filing Date		2001-11-30			
First Named Inventor	Richa	Richard Gore			
Art Unit		2151			
Examiner Name	Kama	l Divecha			
Attorney Docket Number		2705-702			

CERTIFICATION STATEMENT

Diagra can	37	CFR .	1 97	and	1 08	to	make the	annonnista	selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 179(14).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- __ N--

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Michael A. Cofield/	Date (YYYY-MM-DD)	2007-05-08
Name/Print	Michael A. Coffield	Registration Number	54.630

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, U.S. operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. DIN OTS CRID FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the stacked form related to a petient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is civulating; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and the process of the process and the process of the pro

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.